Relmada Therapeutics Stock Target Price and Analyst Consensus
| RLMD Stock | USD 3.72 0.18 4.62% |
The current analyst and expert consensus on Relmada Therapeutics is Hold, with no strong buy opinions. The current projected Relmada Therapeutics target price consensus is 5.50 with 3 analyst opinions. Check out Macroaxis Advice on Relmada Therapeutics to cross-verify analyst projections. Unlike analyst recommendations, Macroaxis provides advice only from the perspective of investor risk tolerance and investment horizon. For information on how to trade Relmada Stock refer to our How to Trade Relmada Stock guide.The most common way Relmada Therapeutics analysts use to provide recommendation to the public is financial statements analysis. Many experts also interview Relmada Therapeutics executives and customers to further validate their buy or sell advice. Please note, the number of analysts providing the opinion is not sufficient to provide adequate consensus on Relmada Therapeutics. We encourage you to use your own analysis of Relmada Therapeutics to validate this analysis. Relmada Therapeutics buy-or-sell recommendation module provides average expert sentiment on the projected Relmada Therapeutics target price to derive its highest and lowest estimates based on projected price volatility of 4.6002.
Lowest Forecast 5.01 | Highest Forecast 6.11 | Target Price 5.5 |
It's important to approach Relmada Therapeutics' target price projections with caution. While they can be useful as part of a broader investment strategy, they are inherently speculative and subject to various kinds of risk, including market volatility and unforeseen external factors. Always consider multiple aspects and do your own research when making investment decisions.
Relmada Therapeutics Target Price Consensus
Relmada target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Relmada Therapeutics' target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 3 | Hold |
Most Relmada analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Relmada stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Relmada Therapeutics, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationRelmada Therapeutics Target Price Projection
Relmada Therapeutics' current and average target prices are 3.72 and 5.50, respectively. The current price of Relmada Therapeutics is the price at which Relmada Therapeutics is currently trading. On the other hand, Relmada Therapeutics' target price is what analysts think the stock is worth. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Current Price
Relmada Therapeutics Market Quote on 14th of February 2026
Target Price
Analyst Consensus On Relmada Therapeutics Target Price
Relmada Therapeutics Analyst Ratings
Relmada Therapeutics' analyst stock recommendations are determined by taking an average estimate of all analysts we track and classifying them as Strong Buy, Buy, Hold, Strong Sell, or Sell. Ratings generally communicate what analysts sense about Relmada Therapeutics stock, and they use a lot of effort and time to analyze it and arrive at a rating. That suggests that analyst recommendations are the outcome of an objective and thorough examination of Relmada Therapeutics' financials, market performance, and future outlook by experienced professionals. Relmada Therapeutics' historical ratings below, therefore, can serve as a valuable tool for investors.Analyst Consensus Breakdown
Average Consensus Estimates
Analysts determine stock price targets through various methods, including financial modeling, peer comparison, and company analysis. The stock price target is the analyst's best estimate of the future price of a stock and is used by investors to make investment decisions. However, it is important to note that stock price targets are not guaranteed, and the actual price of a stock can differ significantly from the target due to various factors such as market conditions, economic events, and company developments.
Steps to utilize Relmada Therapeutics price targets
Relmada Therapeutics' stock target price is an estimate of its future price, usually made by analysts. Using Relmada Therapeutics' target price to determine if it is a suitable investment can be done through the following steps:- Look at Relmada Therapeutics' target prices provided by various analysts and compare them. This can help you gain a more balanced view of the Stock's potential.
- Look at the analyst's track record to determine if they have a history of accurately predicting stock prices.
- Look at the Company's financials, including revenue, earnings, and debt, to determine if it is in good financial health.
- Consider market conditions. For example, take into account the state of the economy, competition, and regulatory environment, to determine if Relmada Therapeutics' stock is likely to perform well.
- Diversify your portfolio and do not rely solely on stock target prices to make investment decisions. Invest in a mix of stocks, bonds, and other assets to manage risk.
Additional Relmada Therapeutics Value Projection Modules
Most investment researchers agree that the mispricing and readjustment of any Stock value happens often and is sometimes even predictable, but there is no strong theory explaining why it happens. The current price of Relmada Therapeutics is a key component of Relmada Therapeutics valuation and have some predictive power on the future returns of a Relmada Therapeutics.Trending Themes
If you are a self-driven investor, you will appreciate our idea-generating investing themes. Our themes help you align your investments inspirations with your core values and are essential building blocks of your portfolios. A typical investing theme is an unweighted collection of up to 20 funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of equities with common characteristics such as industry and growth potential, volatility, or market segment. | Macroaxis Index Invested over 90 shares | |
 | SRI Sustainable Growth Invested over 90 shares | |
 | ESG Investing Sold few shares | |
 | Millennials Best Invested over 90 shares | |
Check out Macroaxis Advice on Relmada Therapeutics to cross-verify analyst projections. Unlike analyst recommendations, Macroaxis provides advice only from the perspective of investor risk tolerance and investment horizon. For information on how to trade Relmada Stock refer to our How to Trade Relmada Stock guide.You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.
Please note, the presentation of Relmada Therapeutics' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Relmada Therapeutics' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Relmada Therapeutics' management manipulating its earnings.